ADC Therapeutics' confirmatory data for Zynlonta muddied by death rates

June 4, 2026 07:01 AM EDT R&DPharmaFDA+ ADC Ther­a­peu­tic­s' con­fir­ma­to­ry da­ta for Zyn­lon­ta mud­died by death rates Reynald Castaneda Deputy Editor ADC Ther­a­peu­tics’ bid to se­cure full ap­proval for Zyn­lon­ta in re­lapsed or re­frac­to­ry dif­fuse large B-cell lym­phoma has been com­pli­cat­ed by death rates in its … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER